Augmenting Adoptive T-cell Immunotherapy by Targeting the PD-1/PD-L1 Axis
- 1 December 2021
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (23) , 5803-5805
Abstract
Cancer immunotherapy utilizing checkpoint blockade antibodies or adoptive cellular therapy (ACT) with tumor-specific T cells has led to unprecedented clinical responses in patients with cancer and has been considered one of the most significant breakthroughs in cancer treatment in the past decade. Nevertheless, many cancers remain refractory to these therapies due to the presence of an immunosuppressive tumor microenvironment. This has led to the innovative idea of combining ACT with checkpoint inhibition. A landmark 2004 study by Blank and colleagues published in Cancer Research was one of the original demonstrations that adoptive transfer of T cells lacking the negative T-cell regulator, PD-1, was able to restore functional T-cell antitumor activity, resulting in rapid regression of established tumors in a preclinical model. This work was instrumental in not only driving clinical studies utilizing checkpoint inhibition but also a new wave of recent trials involving checkpoint blockade in the setting of ACT. See related article by Blank and colleagues, Cancer Res 2004;64:1140–5Keywords
Funding Information
- Cancer Research Irvington (3530)
- Victorian Cancer Agency (MCRF20011)
- NHMRC (APP1136680)
This publication has 10 references indexed in Scilit:
- Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumorsCellular & Molecular Immunology, 2021
- A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent PembrolizumabCancer Discovery, 2021
- CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastomaJournal for ImmunoTherapy of Cancer, 2019
- Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated MannerCancer Immunology Research, 2019
- Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivoNature Biotechnology, 2018
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid TumorsCancer Research, 2016
- Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive TransferClinical Cancer Research, 2016
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T CellsClinical Cancer Research, 2013
- PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible ChemokinesCancer Research, 2012
- PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T CellsCancer Research, 2004